BDNF
BDNF (Brain-Derived Neurotrophic Factor) is a neurotrophin that promotes neuronal survival, synaptic plasticity, and neurogenesis through TrkB receptor signaling, with critical roles in depression, cognitive function, and exercise-mediated brain health.
BDNF (Brain-Derived Neurotrophic Factor) is the most abundant neurotrophin in the mammalian brain, essential for neuronal survival, dendritic arborization, synaptic plasticity, and long-term potentiation (LTP). BDNF signals primarily through the tropomyosin receptor kinase B (TrkB/NTRK2) receptor, activating the MAPK/ERK, PI3K/AKT, and PLCgamma-CaMKII cascades that regulate gene expression programs underlying learning, memory, and mood.
Overview
BDNF was first purified from pig brain by Yves-Alain Barde and Hans Thoenen in 1982 as the second member of the neurotrophin family, after nerve growth factor (NGF). It is the most widely expressed neurotrophin in the CNS, with highest levels in hippocampus, cortex, cerebellum, and basal forebrain. BDNF is synthesized as a 32 kDa precursor (proBDNF) that is proteolytically cleaved to yield the 13.5 kDa mature form. Critically, proBDNF and mature BDNF have opposing biological activities: mature BDNF binds TrkB to promote neuronal survival and synaptic strengthening, while proBDNF binds p75NTR to induce apoptosis and long-term depression (LTD).
The "BDNF hypothesis of depression" posits that stress-induced reductions in BDNF expression in the hippocampus and prefrontal cortex contribute to neuronal atrophy and depressive symptoms, while antidepressant treatments (SSRIs, ketamine, exercise) restore BDNF levels and promote neuroplasticity. This hypothesis has driven extensive research into BDNF-based therapeutics, though BDNF's poor pharmacokinetic properties (short half-life, inability to cross the blood-brain barrier, broad receptor activation) have spurred development of small molecule TrkB agonists and BDNF mimetic peptides as alternatives.
Mechanism of Action
BDNF exerts its effects through two receptor systems with opposing outcomes:
TrkB (NTRK2) Receptor — Pro-survival Signaling: Mature BDNF binds the TrkB receptor with high affinity (Kd ~1-10 pM for the d5 immunoglobulin-like domain), inducing receptor dimerization and autophosphorylation of intracellular tyrosine residues (Y516, Y816). This activates three major downstream cascades: (1) RAS-MAPK/ERK pathway via Shc/Grb2/SOS, driving CREB phosphorylation and expression of plasticity genes (Arc, c-Fos, BDNF itself); (2) PI3K/AKT pathway, promoting neuronal survival by phosphorylating and inactivating pro-apoptotic BAD and activating mTOR for protein synthesis; (3) PLCgamma/IP3/DAG pathway, mobilizing intracellular calcium and activating CaMKII and PKC, which directly modulate synaptic strength. Minichiello (2009) provided a comprehensive review of TrkB signaling specificity.
p75NTR Receptor — Pro-apoptotic Signaling: ProBDNF binds to a complex of p75NTR and sortilin with high affinity, activating JNK and NF-kappaB pathways. JNK activation promotes c-Jun-dependent apoptosis, while p75NTR also activates RhoA, inhibiting neurite outgrowth and promoting growth cone collapse. The balance between proBDNF/p75NTR (pro-apoptotic, LTD-promoting) and mature BDNF/TrkB (pro-survival, LTP-promoting) signaling is a critical determinant of neuronal fate. Teng et al. (2005) demonstrated that proBDNF-p75NTR signaling induces hippocampal LTD and neuronal apoptosis.
Truncated TrkB (TrkB-T1): A dominant-negative splice variant of TrkB lacking the kinase domain. TrkB-T1 is expressed in astrocytes and acts as a BDNF scavenger, sequestering BDNF and limiting its signaling range. TrkB-T1 expression increases with age and in Alzheimer's disease, contributing to BDNF resistance.
Activity-Dependent Secretion: BDNF is stored in dense-core vesicles and released from dendrites and axons in response to neuronal activity (calcium influx, NMDA receptor activation). The Val66Met polymorphism disrupts interaction between the BDNF prodomain and sortilin, impairing vesicular trafficking and activity-dependent secretion without affecting constitutive secretion. Egan et al. (2003) characterized the Val66Met effect on BDNF trafficking and hippocampal function.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Cognitive Function and Memory
BDNF is required for hippocampal LTP, the cellular mechanism of learning and memory. Korte et al. (1995) showed that BDNF knockout mice have severely impaired LTP in hippocampal CA1, which is rescued by exogenous BDNF application. BDNF promotes dendritic spine growth, increases AMPA receptor insertion at synapses, and enhances the late phase of LTP through CREB-dependent gene transcription.
In humans, serum BDNF levels correlate positively with hippocampal volume, episodic memory performance, and processing speed. Val66Met carriers (approximately 20-30% of European and 40-50% of Asian populations) have reduced hippocampal volume, impaired episodic memory, and altered prefrontal cortical function on neuroimaging.
Exercise-Induced BDNF
Exercise is the most potent known inducer of peripheral and central BDNF expression. Acute aerobic exercise increases circulating BDNF by 2-3 fold, with the effect proportional to exercise intensity. Wrann et al. (2013) identified the molecular mechanism: exercise activates PGC-1alpha in skeletal muscle, which induces FNDC5 (irisin precursor). Irisin crosses the blood-brain barrier and stimulates hippocampal BDNF gene expression through ERK-CREB signaling. This muscle-brain endocrine axis explains how peripheral exercise produces central neuroplastic effects.
Sleiman et al. (2016) demonstrated that exercise-induced lactate also crosses the BBB and activates SIRT1-dependent deacetylation of BDNF promoter regions, providing a second exercise-BDNF signaling pathway. Regular exercise training elevates baseline BDNF levels and enhances activity-dependent BDNF secretion.
Neurodegeneration
BDNF levels are reduced in Alzheimer's disease (AD) hippocampus, Parkinson's disease substantia nigra, and Huntington's disease striatum. In AD, amyloid-beta oligomers directly impair BDNF-TrkB signaling by promoting TrkB dephosphorylation and internalization, and by upregulating truncated TrkB-T1. Peng et al. (2005) showed that BDNF delivery reverses synapse loss and improves memory in AD mouse models, but BDNF cannot cross the blood-brain barrier, limiting direct therapeutic application.
In Huntington's disease, mutant huntingtin protein reduces BDNF transcription by sequestering the transcriptional repressor REST/NRSF in the cytoplasm in wild-type cells but failing to do so when mutated. Zuccato et al. (2001) identified this mechanism, showing that cortical BDNF transport to the striatum is reduced in HD, contributing to striatal neurodegeneration.
Depression and Antidepressant Mechanisms
The BDNF hypothesis of depression emerged from observations that stress decreases hippocampal BDNF levels, that chronic antidepressant treatment increases BDNF expression, and that direct BDNF infusion into the hippocampus produces antidepressant-like effects in rodents. Duman & Monteggia (2006) formulated the neurotrophic hypothesis of depression, proposing that reduced BDNF-TrkB signaling in hippocampus and PFC underlies stress-related neuronal atrophy and that antidepressants work by restoring this signaling.
Ketamine's rapid antidepressant effect is mediated through BDNF-TrkB signaling. Autry et al. (2011) showed that ketamine blocks tonic NMDA receptor activity on GABAergic interneurons, disinhibiting glutamatergic neurons, triggering rapid BDNF release and TrkB activation that drives mTOR-dependent synaptogenesis within hours. BDNF conditional knockout mice do not respond to ketamine, establishing BDNF as an essential mediator.
Castrén & Monteggia (2021) reviewed how virtually all antidepressant treatments — SSRIs, SNRIs, ketamine, electroconvulsive therapy, exercise, and psychedelics — converge on BDNF-TrkB signaling to promote neuroplasticity, proposing that antidepressants open a "critical period" of plasticity rather than directly altering mood.
Peptide Mimetics and Small Molecule TrkB Agonists
Because BDNF itself has poor drug-like properties, significant effort has focused on developing TrkB agonists:
7,8-Dihydroxyflavone (7,8-DHF): A naturally occurring flavonoid identified as a selective TrkB agonist (EC50 ~10-100 nM) that mimics BDNF effects. Jang et al. (2010) showed that 7,8-DHF binds the TrkB extracellular domain, promotes TrkB dimerization and autophosphorylation, activates downstream ERK and AKT pathways, and is orally bioavailable and BBB-permeable. It has shown antidepressant, neuroprotective, and memory-enhancing effects in multiple preclinical models.
LM22A-4: A small molecule TrkB partial agonist (EC50 ~200-700 nM) designed through in silico screening of BDNF loop domains. Massa et al. (2010) showed it promotes TrkB activation, neuronal survival, and functional recovery after traumatic brain injury.
BDNF loop peptides: Short peptide mimetics derived from BDNF loop regions (loops 1-4) that interact with TrkB. Cyclic peptide mimetics of BDNF loop 2 show selective TrkB activation in vitro.
Safety Profile
BDNF is an endogenous neurotrophin with well-characterized physiological functions. Direct BDNF administration has been studied primarily in preclinical models due to its poor pharmacokinetic profile.
Known safety considerations include:
- Pro-nociceptive effects: BDNF-TrkB signaling in dorsal horn neurons promotes central sensitization and chronic pain. Exogenous BDNF can exacerbate neuropathic pain states
- Epileptogenic potential: BDNF enhances excitatory synaptic transmission; excessive BDNF-TrkB activation can lower seizure threshold and promote epileptogenesis, particularly in the hippocampus
- ProBDNF toxicity: ProBDNF activates p75NTR-dependent apoptosis; therapies that increase total BDNF must consider the proBDNF:mature BDNF ratio
- Tumor biology: TrkB is an oncogene in neuroblastoma and other cancers. BDNF-TrkB signaling promotes tumor cell survival and chemoresistance. BDNF-enhancing therapies are contraindicated in TrkB-expressing malignancies
- 7,8-DHF safety: Generally well-tolerated in rodent studies at 5-50 mg/kg. No significant hepatotoxicity or behavioral adverse effects reported. Limited human safety data
- LM22A-4 safety: Well-tolerated in preclinical studies. No mutagenicity or overt toxicity at therapeutic doses
- Exercise-induced BDNF: Considered safe and beneficial; the most validated approach to BDNF elevation with no known adverse effects specific to BDNF elevation
Pharmacokinetic Profile
BDNF — Pharmacokinetic Curve
Research Protocols
oral
- 7,8-DHF dosing: 5 mg/kg oral gavage or IP in mice. Bioavailability: ~5% oral (improved with prodrug TrkB agonist R13 at 21.8 mg/kg oral).
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| 7,8-DHF safety | 5-50 mg | Per protocol | — |
| 7,8-DHF dosing | 5 mg, 21.8 mg | Per protocol | —(Route: Oral) |
| LM22A-4 dosing | 50 mg | Per protocol | — |
intrathecal Injection
Intrathecal delivery: 1-12 µg/day.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| BDNF infusion (preclinical) | 0.1-1 µg, 1-12 µg | Per protocol | 7-14 days(Route: Intrathecal) |
Interactions
Peptide Interactions
Dihexa is a hexapeptide that potentiates HGF/c-Met signaling to enhance synaptogenesis. Combined with BDNF-TrkB activation, addresses both neurotrophic and synaptogenic pathways.
Cerebrolysin is a brain-derived peptide mixture that includes BDNF-like neurotrophic activity. May provide sustained, low-level neurotrophic support complementary to acute BDNF enhancement.
These nootropic peptides modulate BDNF expression. Semax increases BDNF mRNA in hippocampus and cortex. Mechanistic rationale for combined neurotrophic support.
What to Expect
What to Expect
Rapid onset expected; half-life of ~10 minutes (mature BDNF in circulation); hours (CNS) indicates fast-acting pharmacokinetics
Exercise protocols: Moderate-to-vigorous aerobic exercise (60-80% VO2max) for 30-60 minutes produces peak BDNF elevation at exercise cessation;...
BDNF infusion (preclinical): Direct hippocampal infusion via osmotic minipump at 0.1-1 µg/day for 7-14 days in rodent depression models.
Continued use as directed
Quality Indicators
What to look for
- Human clinical trials conducted
- Well-established safety profile
- Naturally occurring compound
- Extensive peer-reviewed research base
- Oral administration available
Caution
- Short half-life may require frequent dosing
- No long-term safety data available
Red flags
- Liver toxicity concerns reported
Frequently Asked Questions
References (20)
- [4]Minichiello L, Calella AM, Bhatt D, et al Mechanism of TrkB-mediated hippocampal long-term potentiation Neuron (2002)
- [16]Casarotto MPC, Girber M, Bhatt S, et al Antidepressant drugs act by directly binding to TRKB neurotrophin receptors Cell (2021)
- [17]Castrén E, Monteggia LM Brain-derived neurotrophic factor signaling in depression and antidepressant action Biol Psychiatry (2021)
- [20]Miranda M, Morici JF, Zanoni MB, Bhatt P — Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain Front Cell Neurosci (2022)
- [1]Barde YA, Edgar D, Thoenen H Purification of a new neurotrophic factor from mammalian brain EMBO J (1982)
- [2]Korte M, Carroll P, Wolf E, et al Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor Proc Natl Acad Sci USA (1995)
- [3]Zuccato C, Ciammola A, Bhatt D, et al Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease Science (2001)
- [5]Egan MF, Kojima M, Callicott JH, et al The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function Cell (2003)
- [6]Pang PT, Teng HK, Bhatt E, et al Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity Science (2004)
- [7]Teng HK, Teng KK, Lee R, et al ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin J Neurosci (2005)
- [9]Duman RS, Monteggia LM A neurotrophic model for stress-related mood disorders Biol Psychiatry (2006)
- [10]
- [11]Jang SW, Liu X, Yepes M, et al A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone Proc Natl Acad Sci USA (2010)
- [12]Massa SM, Yang T, Xie Y, et al Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents J Clin Invest (2010)
- [13]Autry AE, Adachi M, Nosyreva E, et al NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature (2011)
- [14]Wrann CD, White JP, Salogiannnis J, et al Exercise induces hippocampal BDNF through a PGC-1alpha/FNDC5 pathway Cell Metab (2013)
- [15]Sleiman SF, Henry J, Al-Haddad R, et al Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body beta-hydroxybutyrate eLife (2016)
- [18]Yang T, Nie Z, Shu H, et al — The role of BDNF on neural plasticity in depression Front Cell Neurosci (2023)
- [21]Lin C, Huang C, Wu YR, et al — Association of BDNF Val66Met with Alzheimer disease biomarkers Neurobiol Aging (2023)
- [8]Peng S, Wuu J, Mufson EJ, Bhatt M Preclinical and clinical evidence for entorhinal-hippocampal BDNF dysregulation in Alzheimer's disease Mol Neurodeg (2005)
B7-33
B7-33 is a single-chain peptide derived from human relaxin-2 (H2-relaxin) that selectively activates the pERK signaling pathway via RXFP1. It demonstrates potent anti-fibrotic effects in preclinical models of cardiac, pulmonary, and renal fibrosis without the cAMP-mediated tumor-promoting risks of the parent molecule.
Beclin-1-Derived Peptides
Beclin-1-derived peptides are synthetic fragments of the essential autophagy regulator Beclin-1, designed to disrupt the inhibitory Beclin-1/BCL-2 interaction and induce autophagy. These peptides are under investigation for cancer therapy, neurodegeneration, and infectious disease through targeted autophagy modulation.